Equities

Guobang Pharma Ltd

605507:SHH

Guobang Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)18.57
  • Today's Change0.270 / 1.48%
  • Shares traded1.87m
  • 1 Year change-9.81%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,1672,4061,832
Total Receivables, Net1,022848656
Total Inventory1,3691,4091,309
Prepaid expenses47757451
Other current assets, total409410319
Total current assets5,4435,1294,567
Property, plant & equipment, net4,3473,3472,635
Goodwill, net0.030.030.03
Intangibles, net359370272
Long term investments19718117
Note receivable - long term------
Other long term assets------
Total assets10,3629,0437,513
LIABILITIES
Accounts payable624432357
Accrued expenses102111104
Notes payable/short-term debt1,5801,207601
Current portion long-term debt/capital leases29----
Other current liabilities, total11611391
Total current liabilities2,4501,8621,154
Total long term debt45200
Total debt2,0601,207601
Deferred income tax11124.16
Minority interest5.15(0.65)(0.39)
Other liabilities, total12149.71
Total liabilities2,9301,8881,167
SHAREHOLDERS EQUITY
Common stock559559559
Additional paid-in capital3,6073,6073,607
Retained earnings (accumulated deficit)3,2662,9892,180
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity7,4327,1556,346
Total liabilities & shareholders' equity10,3629,0437,513
Total common shares outstanding559559559
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.